LDS/Medical Tests/TYMS (Thymidylate Synthetase) Gene Mutation Analysis

TYMS (Thymidylate Synthetase) Gene Mutation Analysis

The TYMS gene is located in the short (p) arm of chromosome 18 at position 11.32 and encodes thymidylate synthase, which is a key enzyme that catalyzes the intracellular transfer of a methyl group to deoxyuridine-5-monophosphate (dUMP) to form deoxythymidine-5-monophosphate (dTMP), which is anabolized in cells to the triphosphate (dTTP). This pathway is the only de novo source of thymidine, an essential precursor for DNA synthesis and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents and is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. Expression of this gene and that of a naturally occurring antisense transcript (mitochondrial enolase superfamily member) vary inversely when cell-growth progresses from late-log to plateau phase. Changes in this gene (amplification, copy number variation and mutations have been associated with breast and colon cancer.

Patients with high tumor levels of TYMS are unlikely to respond to infusions of 5-fluorouracil, whereas patients with low levels show better response rates. Germline polymorphisms in TYMS have also been suggested to assess an individual patients’ response to chemotherapy with fluoropyrimidines prior to treatment. Three genetic variants affecting the expression of TYMS are associated with an increased risk of toxicity after 5-FU administration: (i) a 28-bp tandem repeat variant in the TYMS enhancer region (TYMSER 2R/2R, 2R/3R and 3R/3R); (ii) a single nucleotide polymorphism (SNP) at the 12th nucleotide of the second repeat in the 3R allele leading to a tri-allelic locus (2R, 3RC and 3RG); and (iii) a 6-bp deletion at bp 1494 in the 3′-untranslated region (UTR). However, at this time there are no recommendations for TYMS genetic testing to determine the risk of toxicity prior to administering fluoropyrimidines and there arew no laboratories in the U.S offering this testing.

  • Identifying individuals at increased risk of toxicity when considering 5-fluorouracil (5-FU) and capecitabine chemotherapy treatment
  • For an individual with suspected dihydropyrimidine dehydrogenase (DPD) deficiency, this test may be useful in identifying variants associated with decreased or absent thymidylate synthase enzyme activity

Normal

  • No variants were detected in the TYMS gene. Normal dosing of fluoropyrimidines is supported by this genotype

Abnormal

  • Variant was detected in TYMS gene. Dose reduction of fluoropyrimidines should be considered.

No variants were detected in the TYMS gene. Normal dosing of fluoropyrimidines is supported by this genotype

Allele specific primer extension (ARMS), Polymerase chain reaction (PCR), Conventional sequencing, Next generation sequencing.

Whole Blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Variant detection in DPYD gene, deletion/duplication analysis, gel electrophoresis, FISH.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login